Gardini A, Saragoni L, La Barba G, Serra L, Calistri D, Ulivi P, Casadei A, Frassineti G L, Garcea D
Department of General Surgery, G.B. Morgagni, L. Pierantoni Hospital, Forlì, Italy.
Pathologica. 2012 Aug;104(4):177-81.
Differential diagnosis of liver lesion in the absence of proven primary tumor is still a challenge. We experienced a case of an asymptomatic 14 cm lesion of right hemiliver in a 67 year-old man submitted to right hepatectomy in December 2010. One year before the patient underwent to endoscopic removal of a tubular adenoma of the right colon. Preoperative diagnosis was supported by ultrasound, CT scan, PET and liver biopsy. The patient received 6 cycles of preoperative chemotherapy (FOLFOX) with down-staging of the lesion diameter. Immunohistochemistry on the surgical specimen showed positivity for cytokeratins 19 and 20, CEA, MUC-2, negativity for cytokeratin 7 and a-fetoprotein. Moreover, the neoplastic cells showed a focal positivity with lower intensity for MUC-1 and MUC-5AC. The immunohistochemical profile suggested the possibility of a metastatic tumour from the large bowel, without excluding a primitive mucinous cholangiocarcinoma with intestinal phenotype. At 6 months after intervention, the patient was submitted to chemotherapy (FOLFOX). At present he is in good condition, without radiological signs of recurrence. Oncologists must evaluate the possible benefits of further adjuvant treatments based on the differential diagnosis between a primitive or metastatic liver tumour. In conclusion, correct diagnosis of liver masses is mandatory and remains a challenge that can differentiate either follow-up or surgical and adjuvant treatment. Histology and immunohistochemistry must be related to clinical findings as they may not always be sufficient to reach a correct final diagnosis, and can even be confusing. At present, molecular biology cannot be considered a helpful for diagnosis in these cases.
在未证实存在原发性肿瘤的情况下,肝脏病变的鉴别诊断仍然是一项挑战。我们遇到一例67岁男性患者,其右半肝有一个14厘米无症状病变,于2010年12月接受了右肝切除术。该患者一年前接受了右半结肠管状腺瘤的内镜切除。术前诊断得到了超声、CT扫描、PET和肝脏活检的支持。患者接受了6个周期的术前化疗(FOLFOX),病变直径缩小。手术标本的免疫组化显示细胞角蛋白19和20、癌胚抗原(CEA)、MUC-2呈阳性,细胞角蛋白7和甲胎蛋白呈阴性。此外,肿瘤细胞对MUC-1和MUC-5AC呈局灶性弱阳性。免疫组化特征提示可能为来自大肠的转移性肿瘤,但不排除具有肠型的原发性黏液性胆管癌。干预后6个月,患者接受了化疗(FOLFOX)。目前他状况良好,无复发的影像学迹象。肿瘤学家必须根据原发性或转移性肝肿瘤的鉴别诊断来评估进一步辅助治疗的可能益处。总之,正确诊断肝脏肿块至关重要,仍然是一项挑战,它可以区分后续的随访、手术和辅助治疗。组织学和免疫组化必须与临床发现相关联,因为它们可能并不总是足以得出正确的最终诊断,甚至可能产生混淆。目前,分子生物学在这些病例的诊断中不能被认为是有帮助的。